NSCLC (NTRK-Fusion) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About NSCLC (NTRK-Fusion)
Non-Small Cell Lung Cancer (NSCLC) with an NTRK gene fusion is a specific type of lung cancer that can benefit from targeted therapies. These advanced treatments, while effective, often come with high costs. TheDrugClub is here to help, offering significant savings on essential prescriptions, making your treatment journey more manageable.
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, and within this broad category, there are various subtypes defined by specific genetic alterations. One such alteration is an NTRK gene fusion. This occurs when a portion of the *NTRK* gene breaks off and fuses with another gene, creating an abnormal protein that can drive uncontrolled cell growth, leading to cancer.
Identifying an NTRK fusion is crucial because it allows for a more personalized treatment approach. This specific genetic change is relatively rare, found in a small percentage of NSCLC patients. However, for those who have it, knowing this information opens the door to highly effective targeted therapies. Oncologists typically identify these fusions through biomarker testing, often performed on tumor tissue or blood samples, as part of the diagnostic process.
Traditional chemotherapy may not be the most effective option for patients with an NTRK fusion. Instead, treatment often focuses on targeted therapies known as TRK inhibitors. Medications like larotrectinib (Vitrakvi®) and entrectinib (Rozlytrek®) are designed to specifically block the activity of the abnormal TRK fusion protein, effectively halting or slowing cancer growth while often sparing healthy cells. These drugs are taken orally and have shown promising results in clinical trials for patients with NTRK fusion-positive cancers, including NSCLC. Like all medications, TRK inhibitors
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.